The Lancet Regional Health. Western Pacific (Nov 2020)

Community-based management of epilepsy in Southeast Asia: Two intervention strategies in Lao PDR and Cambodia

  • Farid Boumediene,
  • Channara Chhour,
  • Phetvonsinh Chivorakoun,
  • Vimalay Souvong,
  • Peter Odermatt,
  • Chamroeun Hun,
  • Clémence Thebaut,
  • Mayoura Bounlu,
  • Navuth Chum,
  • Somchit Vorachit,
  • Sina Ros,
  • Samleng Chan,
  • Pierre-Marie Preux

Journal volume & issue
Vol. 4
p. 100042

Abstract

Read online

Background: Epilepsy affects more than 50 million people worldwide, 80% of whom live in low- and middle-income countries (LMICs). In Southeast Asia, the prevalence is moderate (6‰), and the main public health challenge is reducing the treatment gap, which reaches more than 90% in rural areas. Methods: This 12-month comparative study (intervention vs. control areas) assessed the community effectiveness of two different strategies for the identification and home follow-up of people with epilepsy by Domestic Health Visitors for epilepsy (DHVes). In Lao PDR, DHVes were health center staff covering several villages via monthly visits; in Cambodia, DHVes were health volunteers living in the villages. Findings: At baseline, the treatment gap was >95% in Lao PDR and 100% in Cambodia. After 12 months, the treatment gap in Lao PDR decreased by 5·5% (range: 4·0–12·2) in the intervention area and 0·5% (range: 0·4–0·8) in the control area (p<0·0001). In Cambodia, the treatment gap decreased by 34·9% (range: 29·0–44·1) in the intervention area and 8·1% (range: 6·7–10·2) in the control area (p<0·0001). Among the PWEs followed at home by the DHVes, the proportion adhering to drug treatment was 85·2% in Lao PDR and 78·1% in Cambodia. The cost associated with strategy implemented in Cambodia, compared with the control area, was lower than the cost associated with strategy implemented in Lao PDR.” Interpretation: The treatment gap was significantly reduced with both intervention strategies, but the effect was larger in Cambodia. The results of this cost analysis pave the way for scaling-up in rural areas of Lao PDR and Cambodia, and experimental adaptation in other LMICs. Funding: The study was funded by the Global Health Department of Sanofi and Grand Challenges Canada (grant number 0325–04).